Clinical Trials in Organ Transplantation in Children and Adults
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Allergy and Infectious Diseases is preparing to continue funding the Clinical Trials in Organ Transplantation in Children and Adults program to enhance outcomes in solid organ and cellular transplantation through rigorous clinical research and mechanistic investigations. The initiative will support multicenter clinical trials spanning heart, lung, kidney, liver, and intestinal transplants in both pediatric and adult populations, with integrated studies focused on immune responses and biological mechanisms. In addition to traditional organ transplants, the program will also fund trials involving non-hematopoietic cellular therapies, vascularized composite tissue transplants, and the use of bone marrow, mesenchymal stem cells, or other immunologically active cells as adjuncts to transplantation. This effort is authorized under Sections 301 and 405 of the Public Health Service Act and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200, ensuring compliance with federal grant standards. The opportunity is forecasted for release with a point of contact at the DAIT Transplantation Branch Clinical Trial Leadership, accessible through the provided email address for further inquiries.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the continued support of the Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) program. The goal of the CTOT-CA is to improve the outcome of organ transplantation through clinical trials with mechanistic studies. The CTOT-CA will support multicenter clinical trials, with associated studies of immune mechanisms, in heart, lung, kidney, liver, and intestinal transplantation. The program will also support clinical trials of non-hematopoietic cellular transplantation as replacement therapies; vascularized composite tissue transplantation; and transplantation of bone marrow or mesenchymal stem cells, or of immunologically active cells, as adjuncts to organ transplantation. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
